Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients

Assessment of Minimal Residual Disease in Standard-Risk AML

Adam Ivey, Robert K. Hills, Michael A. Simpson et al. · New England Journal of Medicine · 2016 · 836 citations · Full text

Medicine, Hematology, Molecular Genetics +16

Molecular Minimal Residual Disease in Acute Myeloid Leukemia

Mojca Jongen‐Lavrencic, Tim Grob, Diana Hanekamp et al. · New England Journal of Medicine · 2018 · 781 citations · Full text

Medicine, Hematology, Molecular Biology +17

Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial

John A. Liu Yin, Michelle A. O'Brien, Robert K. Hills et al. · Blood · 2012 · 419 citations

Medicine, Molecular Medicine, Oncology +15

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial

Uwe Platzbecker, Martin Wermke, J. Radke et al. · Leukemia · 2011 · 395 citations · Full text

Medicine, Hematology, Pharmacology +17

Monitoring of Minimal Residual Disease in <i>NPM1</i> -Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group

Jan Krönke, Richard F. Schlenk, Kai‐Ole Jensen et al. · Journal of Clinical Oncology · 2011 · 394 citations · Full text

Medicine, Hematology, Oncology +15